BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/24/2024 1:09:01 PM | Browse: 46 | Download: 203
 |
Received |
|
2024-03-27 16:19 |
|
Peer-Review Started |
|
2024-03-27 16:19 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-05-25 02:32 |
|
Revised |
|
2024-06-06 19:08 |
|
Second Decision |
|
2024-06-25 02:44 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-06-25 06:56 |
|
Articles in Press |
|
2024-06-25 06:56 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2024-07-01 02:36 |
|
Typeset the Manuscript |
|
2024-07-08 07:39 |
|
Publish the Manuscript Online |
|
2024-07-24 13:09 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Editorial |
| Article Title |
Recent advances in the diagnostic methods and therapeutic strategies of transthyretin cardiac amyloidosis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Christos Kourek, Alexandros Briasoulis, Dimitrios E Magouliotis, Panagiotis Georgoulias, Grigorios Giamouzis, Filippos Triposkiadis, John Skoularigis and Andrew Xanthopoulos |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Andrew Xanthopoulos, MD, PhD, Postdoctoral Fellow, Department of Cardiology, School of Medicine, University Hospital of Larissa, Mezourlo, Larissa 41110, Greece. andrewvxanth@gmail.com |
| Key Words |
Transthyretin cardiac amyloidosis; Tafamidis; Acoramidis; Eplontersen; Vutrisiran; Patisiran |
| Core Tip |
Transthyretin amyloidosis (ATTR) cardiac amyloidosis is a progressive disease, affecting patients’ functional capacity, survival and quality of life. Incidence and prevalence of ATTR cardiac amyloidosis is increasing over the last years while survival rates are getting improved. Tafamidis is the only disease-modifying approved therapy so far. Novel medical therapies including acoramidis, eplontersen, vutrisiran, patisiran and anti-monoclonal antibody NI006 are being investigated on cardiac function in large, multicenter controlled trials, with potential to become part of the therapeutic armamentarium of the disease. |
| Publish Date |
2024-07-24 13:09 |
| Citation |
<p>Kourek C, Briasoulis A, Magouliotis DE, Georgoulias P, Giamouzis G, Triposkiadis F, Skoularigis J, Xanthopoulos A. Recent advances in the diagnostic methods and therapeutic strategies of transthyretin cardiac amyloidosis. <i>World J Cardiol</i> 2024; 16(7): 370-379</p> |
| URL |
https://www.wjgnet.com/1949-8462/full/v16/i7/370.htm |
| DOI |
https://dx.doi.org/10.4330/wjc.v16.i7.370 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
